High-mobility group box 1 (
HMGB1) shows pro-inflammatory activity in various inflammatory diseases and has been found up-regulated in
chronic obstructive pulmonary disease (
COPD). Lung macrophages play an important role in airway
inflammation and lung destruction in
COPD, yet whether
HMGB1 is involved in cigarette
smoke (CS)-induced lung macrophage dysfunction is unknown. We sought to evaluate the intracellular localization and release of
HMGB1 in lung macrophages from
COPD patients and CS-exposed mice, and to investigate the role of
HMGB1 in regulating autophagy in CS extract (CSE)-treated lung macrophages (MH-S cells). Our results showed that
HMGB1 was highly expressed in lung tissues and sera of
COPD patients and CS-exposed mice, along with predominantly cytoplasmic exporting from nuclei in lung macrophages. In vitro experiments revealed that CSE promoted the expression, nucleocytoplasmic translocation and release of
HMGB1 partly via the
nicotinic acetylcholine receptor (nAChR). Blockade of
HMGB1 with chicken anti-HMGB1 polyclonal antibody (anti-HMGB1) or
glycyrrhizin (Gly) attenuated the increase of LC3B-II and
Beclin1, migration and p65 phosphorylation, suggesting the involvement of
HMGB1 in autophagy, migration and NF-κB activation of lung macrophages.
Hydroxychloroquine (CQ), an autophagy inhibitor, enhanced the increase of LC3B-II but not
Beclin1 in CSE or rHMGB1-treated MH-S cells, and inhibition of autophagy by CQ and
3-methyladenine (3-MA) abrogated the migration and p65 phosphorylation of CSE-treated cells. These results indicate that CS-induced
HMGB1 translocation and release contribute to migration and NF-κB activation through inducing autophagy in lung macrophages, providing novel evidence for
HMGB1 as a potential target of intervention in
COPD.